Kjaer K W, Eiberg H, Hansen L, van der Hagen C B, Rosendahl K, Tommerup N, Mundlos S
Wilhelm Johannsen Centre for Functional Genome Research, Department of Medical Biochemistry and Genetics, University of Copenhagen, Denmark.
J Med Genet. 2006 Mar;43(3):225-31. doi: 10.1136/jmg.2005.034058. Epub 2005 Jul 13.
Brachydactyly type A2 (OMIM 112600) is characterised by hypoplasia/aplasia of the second middle phalanx of the index finger and sometimes the little finger. BDA2 was first described by Mohr and Wriedt in a large Danish/Norwegian kindred and mutations in BMPR1B were recently demonstrated in two affected families.
We found and reviewed Mohr and Wriedt's original unpublished annotations, updated the family pedigree, and examined 37 family members clinically, and radiologically by constructing the metacarpo-phalangeal profile (MCPP) pattern in nine affected subjects. Molecular analyses included sequencing of BMPR1B, linkage analysis for STS markers flanking GDF5, sequencing of GDF5, confirmation of the mutation by a restriction enzyme assay, and localisation of the mutation inferred from the very recently reported GDF5 crystal structure, and by superimposing the GDF5 protein sequence onto the crystal structure of BMP2 bound to Bmpr1a.
A short middle phalanx of the index finger was found in all affected individuals, but other fingers were occasionally involved. The fourth finger was characteristically spared. This distinguishes Mohr-Wriedt type BDA2 from BDA2 caused by mutations in BMPR1B. An MCPP analysis most efficiently detected mutation carrier status. We identified a missense mutation, c.1322T>C, causing substitution of a leucine with a proline at amino acid residue 441 within the active signalling domain of GDF5. The mutation was predicted to reside in the binding site for BMP type 1 receptors.
GDF5 is a novel BDA2 causing gene. It is suggested that impaired activity of BMPR1B is the molecular mechanism responsible for the BDA2 phenotype.
A2型短指症(OMIM 112600)的特征是食指中节指骨发育不全/发育不良,有时小指也会出现这种情况。BDA2最初由莫尔(Mohr)和维里特(Wriedt)在一个丹麦/挪威大家族中描述,最近在两个患病家族中证实了BMPR1B基因存在突变。
我们查找并查阅了莫尔和维里特最初未发表的注释,更新了家族谱系,并对37名家族成员进行了临床检查,通过为9名患病个体构建掌指轮廓(MCPP)模式进行放射学检查。分子分析包括对BMPR1B进行测序、对GDF5侧翼的STS标记进行连锁分析、对GDF5进行测序、通过限制性酶切分析确认突变,以及根据最近报道的GDF5晶体结构推断突变的定位,并将GDF5蛋白序列叠加到与Bmpr1a结合的BMP2晶体结构上。
在所有患病个体中均发现食指中节指骨短小,但其他手指偶尔也会受累。无名指通常不受影响。这将莫尔 - 维里特型BDA2与由BMPR1B基因突变引起的BDA2区分开来。MCPP分析最有效地检测出突变携带者状态。我们鉴定出一个错义突变,c.1322T>C,导致GDF5活性信号域内第441位氨基酸残基处的亮氨酸被脯氨酸取代。该突变预计位于1型BMP受体的结合位点。
GDF5是一种新型的导致A2型短指症的基因。提示BMPR1B活性受损是导致A2型短指症表型的分子机制。